Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
We are a pharmaceutical company dedicated to the development of best-in-class ther...
We are a pharmaceutical company dedicated to th...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...
Reata is a clinical-stage biopharmaceutical com...
Alkermes plc is a fully integrated, global biopharmaceutical company developing in...
Alkermes plc is a fully integrated, global biop...
Join the National Investor Network and get the latest information with your interests in mind.